Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;32(4):977-988.
doi: 10.1007/s11136-022-03302-z. Epub 2022 Nov 21.

Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study

Macarena Lozano-Lorca  1   2 , Rocío Barrios-Rodríguez  1   2   3 , Daniel Redondo-Sánchez  2   3   4 , José-Manuel Cózar  5 , Miguel Arrabal-Martín  6 , Marta García-Caballos  7 , Inmaculada Salcedo-Bellido  1   2   3 , María-José Sánchez  1   2   3   4 , José-Juan Jiménez-Moleón  1   2   3 , Rocío Olmedo-Requena  8   9   10
Affiliations

Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study

Macarena Lozano-Lorca et al. Qual Life Res. 2023 Apr.

Abstract

Purpose: To analyse the Health-Related Quality of Life (HRQoL) at diagnosis of patients with prostate cancer (PCa) according to tumour extension and urinary symptomatology and to explore factors associated with HRQoL.

Methods: 408 Controls and 463 PCa cases were included. Eligibility criteria were a new diagnosis of PCa (cases), 40-80 years of age, and residence in the participating hospitals' coverage area for ≥ 6 months before recruitment. HRQoL was evaluated using the 12-Item Short-Form Health Survey, Mental (MCS) and Physical Component Summaries (PCS), and urinary symptoms with the International Prostate Symptom Score. HRQoL scores for all PCa cases, according to tumour extension and urinary symptoms, were compared with controls. In addition, information about lifestyles and comorbidities was collected and its association with low HRQoL (lower scores) were explored using logistic regression models.

Results: Overall cases had similar PCS score, but lower MCS score than controls. The lowest standardised scores for both PCS and MCS were reached by cases with severe urinary symptoms and a metastatic tumour [mean (SD); PCS: 41.9 (11.5), MCS: 42.3 (10.3)]. Having "below" PCS and MCS scores was associated with the presence of three or more comorbidities in the cases [aOR = 2.86 (1.19-6.84) for PCS and aOR = 3.58 (1.37-9.31) for MCS] and with severe urinary symptomatology [aOR = 4.71 (1.84-12.08) for PCS and aOR = 7.63 (2.70-21.58) for MCS].

Conclusion: The mental dimension of HRQoL at diagnosis of patients with PCa was lower than in controls, especially for cases with severe urinary symptoms and a metastatic tumour. Comorbidities and urinary symptoms were variables associated with the HRQoL of PCa cases.

Keywords: Health-related quality of life; Prostate cancer; Tumour extension; Urinary symptomatology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow-chart of participants in the CAPLIFE study
Fig. 2
Fig. 2
Scores for the 8 dimensions of the Short-Form Health Survey version 2 (SF-12 v2) in prostate cancer (PCa) cases and controls aged 65–74 years (the largest group)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Rawla P. Epidemiology of prostate cancer. World Journal of Oncology. 2019;10(2):63–89. doi: 10.14740/wjon1191. - DOI - PMC - PubMed
    1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer. 2018;103:356–387. doi: 10.1016/j.ejca.2018.07.005. - DOI - PubMed
    1. Grosclaude P, Roche L, Fuentes-Raspall R, Larrañaga N. Trends in net survival from prostate cancer in six European Latin countries. European Journal of Cancer Prevention. 2017;26:S114–S120. doi: 10.1097/CEJ.0000000000000304. - DOI - PubMed